Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00103571
Status:
COMPLETED
Last Update Posted:
2007-11-06
First Post:
2005-02-10
Brief Title:
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to assess similarities and differences in the efficacy how well the drug works safety and side effects of olanzapine and aripiprazole in patients with schizophrenia schizoaffective disorder or schizophreniform disorder
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| F1D-US-HGLS | None | None | None |